Celgene wins Chinese regulatory OK for Revlimid

Mon Feb 11, 2013 7:35pm IST

Related Topics

Stocks

   

(Reuters) - Celgene Corp on Monday said its drug Revlimid won full regulatory approval in China for patients with relapsed or refractory multiple myeloma, a type of cancer that starts in the plasma cells in the bone marrow.

Multiple myeloma is the second most commonly diagnosed blood cancer. There are an estimated 750,000 people with the disease worldwide, according to the International Myeloma Foundation.

Celgene said it expects the drug to be available to Chinese patients late in the second quarter of 2013.

In addition, the biotechnology company said Revlimid, or lenalidomide, was granted priority review by the U.S. Food and Drug Administration as a treatment for patients with relapsed or refractory mantle cell lymphoma.

Revlimid is approved in combination with dexamethasone for the treatment of patients with multiple myeloma, who have received at least one prior therapy, in almost 70 countries, including the Americas and Europe.

It is also approved in the United States, Canada, Switzerland, Australia, New Zealand and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anemia.

(Reporting By Debra Sherman; Editing by Gerald E. McCormick)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Ebola Outbreak

HEALTH SHOWCASE

H5N6 Bird Flu

H5N6 Bird Flu

China poultry farm hit in new outbreak of H5N6 bird flu.  Full Article 

Weight Loss

Weight Loss

Low-carb diets may beat low-fat options for weight loss, heart health.  Full Article 

TV and Snacking

TV and Snacking

High-action TV shows lead to more snacking: study.  Full Article 

Fighting Cyberbullies

Fighting Cyberbullies

Family dinners may help kids cope with cyberbullying.  Full Article 

Price Factor

Price Factor

Pricing is key for new heart drugs challenging cheap generics.  Full Article 

Diabetes Care

Diabetes Care

Pistachios may help reduce diabetes risk: study.  Full Article 

'Exciting' Drug

'Exciting' Drug

'Most exciting ever' Novartis drug points to huge sales.  Full Article